ioxaglic acid
Ioxaglic acid (trade name Hexabrix) is an iodine containing molecule used as a low-osmolality contrast medium. Ioxaglic Acid is an ionic tri-iodinated benzoate used as a contrast agent in diagnostic imaging. Like other organic iodine compounds, ioxaglic acid blocks x-rays and appears opaque on x-ray film, thereby enhancing the visibility of structure and organs during angiography, arteriography, arthrography, cholangiography, urography, and computed tomography (CT) scanning procedures. Ioxaglic acid has low osmolarity and is therefore associated with few side effects compared to older contrast agents. — NCATS
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started Feb 1, 2013 (NCT01848899)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
- Unspecified targetOTHER
Diagnostic
- Unspecified targetContrast agent
contrast agent
Chemistry & pharmacology
SMILES
CNC(=O)C1=C(I)C(N(C)C(C)=O)=C(I)C(C(=O)NCC(=O)NC2=C(I)C(C(=O)NCCO)=C(I)C(C(O)=O)=C2I)=C1I- Mol. weight
- 1268.8791 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaIoxaglic acid ↗
- NCATSZ40X7EI2AF ↗
- ChEMBLCHEMBL1201291 ↗
- ChEMBLCHEMBL1200743 ↗
- ChEMBLCHEMBL1200508 ↗
Also known as
- hexabrix 160
- ioxaglate
- ioxaglate
- ioxaglate
- ioxaglic acid
- ioxaglic acid
- ioxaglic acid
- ioxaglic acid
- ioxaglic acid
- ioxaglic acid
- ioxaglic acid
- p-286
- p-286
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01848899 | Phase 4 | Feb 1, 2013 | Guerbet, New York University |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Guerbet | For profit | 1 | 0 | 1 | 2013 |
| New York University | Academic/Hospital | 1 | 1 | 1 | 2013 |